S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.55 (-0.23%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.55 (-0.23%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.55 (-0.23%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.55 (-0.23%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
Log in
NASDAQ:REPL

Replimune Group Stock Forecast, Price & News

$23.09
+1.51 (+7.00 %)
(As of 09/29/2020 12:37 PM ET)
Add
Compare
Today's Range
$21.59
Now: $23.09
$23.09
50-Day Range
$20.64
MA: $23.81
$27.00
52-Week Range
$8.58
Now: $23.09
$27.69
Volume3,429 shs
Average Volume159,815 shs
Market Capitalization$930.25 million
P/E RatioN/A
Dividend YieldN/A
Beta3.2
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More
Replimune Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPL
CUSIPN/A
CIKN/A
Phone781-222-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-52,630,000.00

Miscellaneous

Employees62
Market Cap$930.25 million
Next Earnings Date11/9/2020 (Estimated)
OptionableNot Optionable
$23.09
+1.51 (+7.00 %)
(As of 09/29/2020 12:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Replimune Group (NASDAQ:REPL) Frequently Asked Questions

How has Replimune Group's stock price been impacted by COVID-19?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REPL stock has increased by 93.5% and is now trading at $23.09.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Replimune Group?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Replimune Group
.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Replimune Group
.

How were Replimune Group's earnings last quarter?

Replimune Group Inc (NASDAQ:REPL) released its quarterly earnings results on Friday, August, 7th. The company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44).
View Replimune Group's earnings history
.

What price target have analysts set for REPL?

7 brokerages have issued twelve-month price objectives for Replimune Group's shares. Their forecasts range from $12.50 to $40.00. On average, they anticipate Replimune Group's stock price to reach $27.07 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Replimune Group
.

Are investors shorting Replimune Group?

Replimune Group saw a increase in short interest in September. As of September 15th, there was short interest totaling 687,300 shares, an increase of 21.5% from the August 31st total of 565,600 shares. Based on an average daily volume of 213,500 shares, the days-to-cover ratio is presently 3.2 days. Approximately 3.5% of the shares of the stock are sold short.
View Replimune Group's Short Interest
.

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)
  • Dr. Robert Coffin, Pres, CEO & Director (Age 54)
  • Dr. Colin Love, Chief Operating Officer (Age 61)
  • Dr. Pamela Esposito, Chief Bus. Officer (Age 45)
  • Stephen Gorgol, Chief Accounting Officer

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $23.09.

How big of a company is Replimune Group?

Replimune Group has a market capitalization of $930.25 million. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Replimune Group employs 62 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.